Eli Lilly and Company (LLY)

Market Cap	935.38B +28.5%
Revenue (ttm)	65.18B +44.7%
Net Income	20.64B +94.9%
EPS	22.95 +96.0%
Shares Out	895.38M
PE Ratio	45.52
Forward PE	30.59
Dividend	$6.92 (0.66%)
Ex-Dividend Date	Feb 13, 2026

Volume	3,423,782
Open	1,077.09
Previous Close	1,058.18
Day's Range	1,042.92 - 1,106.94
52-Week Range	623.78 - 1,133.95
Beta	0.39
Analysts	Strong Buy
Price Target	1,155.33 (+10.59%)
Earnings Date	Feb 4, 2026

About LLY

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1876
• Employees: 47,000
• Stock Exchange: NYSE
• Ticker Symbol: LLY
• Website: https://www.lilly.com

Financial Performance

In 2025, Eli Lilly's revenue was $65.18 billion, an increase of 44.70% compared to the previous year's $45.04 billion. Earnings were $20.64 billion, an increase of 94.90%.

Analyst Summary

According to 18 analysts, the average rating for LLY stock is "Strong Buy." The 12-month stock price target is $1,155.33, which is an increase of 10.59% from the latest price.

Price Target

$1,155.33

(10.59% upside)

Analyst Consensus: Strong Buy